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Since January 2002 Pseudomonas sp. strains resistant to carbapenems and ceftazidime have been routinely
screened as part of the SENTRY Antimicrobial Surveillance Program for metallo--lactamase production, and
their resistance determinants have been analyzed. Pseudomonas aeruginosa index strain 101–4704, which
harbors a novel blaIMP variant, blaIMP-16, was isolated in April 2002 from a 60-year-old man in Brası´lia, Brazil.
blaIMP-16 was found on the chromosome of the P. aeruginosa index strain, and the deduced amino acid sequence
(IMP-16) showed the greatest identities to IMP-11 (90.3%) and IMP-8 (89.5%). Sequence analysis revealed that
blaIMP-16 was associated with a class 1 integron, which also encoded aminoglycoside-modifying enzymes.
Downstream of blaIMP-16 resided an open reading frame, which consisted of a new aminoglycoside-modifying
gene, namely, aac(6)-30, which was fused with aac(6)-Ib. The amino acid sequence of the aac(6)-30 putative
protein showed the most identity (52.7%) to the sequence of AAC(6)-29b described previously. The fourth gene
cassette constituted aadA1. The steady-state kinetics of IMP-16 demonstrated that the enzyme preferred
cephalosporins and carbapenems to penicillins. The main functional difference observed among the kinetic
values for IMP-16 compared to those for other IMPs was a lack of cefoxitin hydrolysis and a lower kcat/Km value
for imipenem (0.36 M1  s1). This report further emphasizes the spread of metallo--lactamase genes and
their close association with various aminoglycoside resistance genes.
The carbapenems represent important therapeutic options
for serious infections caused by Pseudomonas aeruginosa, es-
pecially multidrug-resistant strains. The activities of these com-
pounds are mainly related to their rapid permeation across
bacterial membranes and their stabilities against most -lacta-
mases (3). However, as with other antimicrobial agents, car-
bapenem-resistant P. aeruginosa strains continue to be isolated
with an increasing frequency from nosocomial infection
sources. Trends have been observed that demonstrate a de-
crease in carbapenem susceptibility among P. aeruginosa
strains isolated from hospitalized patients in Latin America
(from 83.0 to 64.4% between the years 1997 and 2001 [P 
0.001; odds ratio  2.70; 95% confidence interval  1.88 to
3.89]) (2).
The mechanisms responsible for carbapenem resistance in-
clude decreased outer membrane permeability (porin muta-
tions), up-regulation of multidrug efflux pumps, substantial
production of a chromosomal ampC -lactamase or a class D
-lactamase (often accompanied by porin changes), and pro-
duction of a class B -lactamase (1, 22). The class B enzymes,
or metallo--lactamases (MLs), are zinc-dependent enzymes
that catalyze the hydrolysis of a broad range of -lactams,
including carbapenems, using zinc ions as metal cofactors (44).
To date, three types of mobile ML genes have been reported.
In 1994, the IMP-type ML gene was first reported in Japan
(29), and since then, IMP ML-producing strains have been
reported from many different countries worldwide (4, 6, 7, 13,
46, 51). The VIM-type enzymes were first reported from Italy
in 1999, and strains producing these enzymes have now been
reported from European countries as well as Asia and the
Americas (21, 25, 35, 47, 50). Some studies have indicated the
presence of ML genes among multidrug-resistant strains in
Brazil (10, 31), and this evidence was later confirmed by the
report of a P. aeruginosa strain producing a new ML subclass,
namely, SPM-1 (26, 48).
Most mobile ML genes are part of a gene cassette consist-
ing of a single gene and a downstream recombination site,
known as a 59-base element (59-be) (36). The genes are usually
associated with class 1 and 3 integrons (5), apart from SPM-1,
for which the genetic environment has recently been described
(34). Among ML genes, the class 1 integron is the most
commonly encountered and consists of a 5 conserved se-
quence (5-CS), which constitutes an intI1 gene coding for an
integrase; a recombination site, attI1; a promoter; and usually,
a 3-CS that possesses the qacE1 and sul1 genes (9). Inte-
grons are able to capture gene cassettes by a site-specific re-
combination event between two recombination sites, one in the
integron and one in the cassette. Both recombination sites
confer mobility due to their recognition by the integrase that
catalyzes the integration of the gene cassette between attI1 in
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the integron and the 59-be in the gene cassette. Although
recombination between different sites has been documented, it
occurs at a very low frequency (30, 36).
In the present study, we describe the blaIMP-16 variant, the
kinetic parameters for IMP-16, and the genetic context of the
blaIMP-16-carrying integron, which also included a fused form
of aminoglycoside-modifying resistance gene aac(6)-30/
aac(6)-Ib, found in a P. aeruginosa strain (strain 101-4704)
isolated from the Latin American component of the SENTRY
Antimicrobial Surveillance Program.
MATERIALS AND METHODS
Clinical context of carbapenem-hydrolyzing P. aeruginosa index strain (strain
101–4704). The SENTRY Program was established in 1997 to monitor the most
important pathogens and antimicrobial resistance patterns of the organisms
causing nosocomial and community-acquired infections via a broad network of
sentinel hospitals distributed by geographic location and bed capacity. As part of
that study, a P. aeruginosa index strain (strain 101-4704) was isolated from a
60-year-old man with bronchogenic carcinoma who was first admitted to the
Hospital de Base do Distrito Federal, Brası´lia, Brazil, in May 2001. A pneumo-
nectomy of the right lung was performed in July 2001, and in August 2001 the
patient developed severe pneumonia and required mechanical ventilation. An
empyema was also diagnosed, and drainage was performed. The patient’s symp-
toms improved, but he had three other episodes of pneumonia and remained in
the intensive care unit for 151 days.
Several pathogens were recovered from respiratory specimens, including P.
aeruginosa, an Acinetobacter sp., and Stenotrophomonas maltophilia, but all blood
cultures were negative. When the patient was in the intensive care unit he
received meropenem at 1 g every 8 h (for 54 days), amikacin at 500 mg every 12 h
(q12h; for a total of 42 days), trimethoprim-sulfamethoxazole at 800 mg every 6 h
(for 16 days), ciprofloxacin at 400 mg q12h (for 14 days), and vancomycin at 1 g
q12h (for 21 days). The patient was subsequently discharged. In April 2002, he
was readmitted with cough and dyspnea. Pulmonary secretions collected during
a bronchoscopy yielded the P. aeruginosa index strain, strain 101-4704. No anti-
microbial was administered to the patient, and he was discharged in May 2002.
Strain 101-4704 was resistant to several -lactams, including meropenem and
imipenem (MICs  16 g/ml), but was susceptible to aztreonam, piperacillin,
and piperacillin-tazobactam. The microorganism was also resistant to most ami-
noglycosides, including gentamicin, tobramycin, and netilmicin, but remained
susceptible to amikacin and the fluoroquinolones.
Susceptibility testing. The susceptibilities of all isolates collected in the SEN-
TRY Program were tested by the reference broth microdilution method de-
scribed by the National Committee for Clinical Laboratory Standards (NCCLS)
(27). The aminoglycoside resistance profiles of Escherichia coli DH5	 harboring
recombinant plasmids were assayed by MIC determinations by either the refer-
ence agar dilution method or Etest (AB Biodisk, Solna, Sweden) methodology,
according to the guidelines of NCCLS and the manufacturer, respectively. An-
timicrobial agents were obtained from the respective manufacturers; and quality
control was performed by concurrent testing of E. coli ATCC 25922, P. aerugi-
nosa ATCC 27853, Staphylococcus aureus ATCC 29213, and Enterococcus fae-
calis ATCC 29212.
Phenotypic detection of -lactamase enzymes. Isolates were initially screened
for the production of MLs by the modified disk approximation test. Briefly, a
100-mm-diameter Mueller-Hinton agar plate was inoculated with a 0.5 McFar-
land standard suspension from a fresh overnight culture. Imipenem, meropenem,
and ceftazidime disks were strategically aligned around disks that contained
either EDTA (750 g) or thiolactic acid (0.3 l) as ML inhibitors. The test
result was read after 20 h of incubation at 35°C. Any appearance of either an
elongated or a phantom zone between the carbapenems and/or ceftazidime and
either one of the disks containing an ML inhibitor was considered a positive test
result. IMP-2-producing Acinetobacter baumannii 54/97 was used as a positive
control. ML Etest strips were used to confirm the disk approximation test
results. In addition, ceftazidime–ceftazidime-clavulanic acid and cefepime–
cefepime-clavulanic acid ESBL Etest strips were used to evaluate the organisms
for the production of extended-spectrum -lactamases (ESBLs).
Bacterial strains, plasmids, conjugation, and transformation. The bacterial
strains and plasmids used in this study are described in Table 1. Plasmid DNA
from P. aeruginosa 101-4704 was extracted with a plasmid DNA Midi kit (Qiagen,
Chatsworth, Calif.). The transfer of -lactam resistance markers from strain
101–4704 into E. coli DH5	 and a rifampin-resistant (Rifr) mutant of P. aerugi-
nosa pA01 was performed with a Gene Pulser apparatus (Bio-Rad, Watford,
United Kingdom) that was set at 2.5 kV, 25 F, and 400 
. The transfer of
resistance to Rifr mutant E. coli K-12 and P. aeruginosa pAO1 was also per-
formed by conjugation experiments, as described previously (40). Strains DH5	,
pAO1, and K-12 harboring the possible plasmids of strain 101-4704 were selected
by plating the strains onto nutrient agar plates containing ceftazidime (10 g/ml)
or ceftazidime and rifampin (500 g/ml).
Analytical IEF. The -lactamase extract from P. aeruginosa strain 101-4704
was obtained by cell lysis with a BugBuster apparatus (Novagen, Nottingham,
United Kingdom), and isoelectric focusing (IEF) was performed with a NOVEX
apparatus (Invitrogen, Paisley, United Kingdom). The focused -lactamases
were detected by overlaying the gel with nitrocefin solution (150 M; Microbi-
ology Systems, Cockeysville, Md.). The -lactamase pIs were estimated by linear
regression, obtained by comparison to the pIs of reference proteins by using a
standard IEF marker containing proteins with a pI range of 4.5 to 9.5 (Bio-Rad).
PCR and DNA sequencing. The SENTRY Program strains with positive ML
phenotypic test results were screened for ML genes by standard PCRs (40) with
Extensor Hi-Fidelity PCR Master Mix (ABgene, Surrey, United Kingdom) and
primers targeting conserved regions of blaVIM, blaIMP, and blaSPM. Additional
primers designed to target the 5-CS and 3-CS regions of the class 1 integron
were used to amplify the blaIMP-16-containing integron resident in P. aeruginosa
101-4704. These primers yielded PCR products, and both strands were se-
quenced on a Perkin-Elmer system 377 DNA sequencer (Advanced Biotechnol-
ogy Centre, London, United Kingdom). The DNA sequences were found to
overlap, and these were assembled to produce a contiguous sequence of 4,333 bp.
TABLE 1. Bacterial strains and plasmids used in this study
Strain or plasmid Genotype or phenotype Source orreference
Strains
P. aeruginosa 101-4704 Carbapenem-hydrolyzing clinical isolate This study
Rifampin-resistant P. aeruginosa pAO1 algU algD algW mucD Alg (wild type) Rif 14
Rifampin-resistant E. coli K-12 Rif Nalr This study
XL10-Gold Kan E. coli cell Tetr (mcrA) 183 (mcrCB-hsdSMR-mrr)173 endA1 supE44 thi-1 recA1 gyrA96
relA1 lac Hte [F proAB lac1qZ  M15 Tn10 (Tetr) Tn5 (Kanr) Amy]
Stratagene
E. coli DH5	 supE44 lacU169 (80lacZM15) hsdR17 recA1 endA1 gyrA96 thi-1 relA1 48
Plasmids
pPCRScriptCam SK() Chloramphenicol resistant Stratagene
pREM-1 819-bp PCR product from aac(6)-30 cloned into pPCRScriptCam SK() This study
pREM-2 1429-bp PCR product from aac(6)-30/aac(6)-Ib cloned into pPCRScriptCam
SK()
This study
pREM-3 748-bp PCR product from aac(6)-Ib cloned into pPCRScriptCam SK() This study
pREM-4 1,817-bp PCR product from blaIMP-16 and aac(6)-30 cloned into
pPCRScriptCam SK()
This study
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Recombinant DNA methodology. The blaIMP-16 and aminoglycoside resistance
genes were amplified by PCR. Primers were designed to amplify specific indi-
vidual genes or sets of genes that could subsequently be cloned into pPCRScript-
Cam SK() (Stratagene Cloning Systems, La Jolla, Calif.). blaIMP-16 and the
downstream region were amplified with primer set Int1-1F–aacA4FR. The fused-
form gene aac(6)-30/aac(6)-Ib was amplified with primer set IMP-16FF–
aadA1FR. Additionally, aac(6)-30 and aac(6)-Ib were separately amplified
with primer sets IMP-16FF–aacA4FR and aacA30FF-aadA1FR, respectively
(Fig. 1). The ribosome-binding site and the stop codon were included in order to
allow gene expression. This technique yielded several subclones of the original
integron that were subsequently screened by PCR with primer set M13F-M13R,
and the presence of the insertion and its orientation were confirmed by sequenc-
ing. Because XL10-Gold Kan ultracompetent E. coli cells are intrinsically resis-
tant to streptomycin due to a chromosomal mutation, the recombinant plasmids
were transferred into E. coli DH5	, and their respective antimicrobial resistance
profiles were evaluated.
-Lactamase purification. A single colony of E. coli harboring recombinant
plasmid pREM-4 was grown overnight in 10 ml of nutrient broth containing
ceftazidime (10 g/ml) and chloramphenicol (30 g/ml) at 37°C. The cells were
harvested by centrifugation (4,000  g for 10 min at 4°C) and then added to 4
liters of terrific broth (12% tryptone, 20% yeast extract, 0.4% glycerol, 0.17 M
monopotassium phosphate, 0.72 M dipotassium phosphate) for aerobic growth in
an orbital shaker for 24 h at 37°C. The cells were again harvested, as described
above, and were resuspended in 100 ml of 10 mM HEPES buffer containing 50
M ZnCl2 (pH 7.5). The periplasm preparation was obtained by the addition of
400 l of lysozyme solution (20 mg/ml; Sigma-Aldrich, Poole, United Kingdom)
and 400 l of calcium chloride (147 mg/ml). Cells debris was removed by cen-
trifugation (9,000  g for 20 min at 4°C), the supernatant was loaded onto a
Q-Sepharose (quaternary ammonium) HR 16/50 column (Amersham Pharmacia
Biotech, Uppsala, Sweden), and then the proteins were eluted with a linear NaCl
gradient (0 to 1 M) at a flow rate of 2 ml/min. Fractions containing -lactamase
activity were pooled, concentrated, and then injected onto a Superdex 75 HR
10/30 column (Amersham Pharmacia Biotech) that had previously been equili-
brated with HEPES buffer containing 50 M ZnCl2 and 0.2 M NaCl. Proteins
were eluted at a flow rate of 0.7 ml/min. During the purification procedure the
presence of -lactamase activity was monitored with nitrocefin solution.
Protein electrophoretic technique. The enzyme that was obtained was submit-
ted to sodium dodecyl sulfate-polyacrylamide gel electrophoresis in a Mini-
Protein II apparatus (Bio-Rad) in order to confirm its purity.
Kinetic measurements. The reactions for kinetic measurements were per-
formed at 20°C with 20 l of enzyme in 1 ml of HEPES buffer containing 50 M
ZnCl2 (pH 7.0). Hydrolysis was measured by observing the changes in absor-
bance due to the opening of the -lactam ring at a range of concentrations in a
Lambda 35 spectrophotometer (Perkin-Elmer, Cambridge, United Kingdom).
The steady-state kinetic parameters Km (in micromolar units) and kcat (per
second) were deduced from the initial rates of hydrolysis by using the Hanes-
Woolf plot (41). The extinction coefficients and wavelengths for each antimicro-
bial agent evaluated were those described previously (26).
Computer sequence analysis. The nucleotide sequences were compared by
using software available over the Internet (http://www.ebi.ac.uk/fasta33/). The
nucleotide sequences and their deduced protein products, alignments, and phy-
logenetic relationships were determined with the Lasergene software package
(DNASTAR, Madison, Wis.). The putative cleavage site of the signal sequence
of IMP-16 was identified by computer analysis with software available at the
Center for Biological Sequence Analysis website (http://www.cbs.dtu.dk).
Nucleotide sequence accession number. The nucleotide sequence of the
blaIMP-16-containing integron described in this paper has been submitted to the
EMBL/GenBank/DDBJ sequence databases and assigned accession number
AJ584652.
RESULTS
Genetic environment of blaIMP-16. The blaIMP-16 gene was
located in a class 1 integron that contained a 5-CS composed
of integrase gene intI1, the attI1 recombination site, and a
promoter region (Fig. 2). The P1 promoter (35 [TGGACA];
10 [TAAGCT]) was identified and was found to contain two
hexamers separated by 17 bp, followed by a second promoter,
P2 (35 [TTGTTA]; 10 [TACAGT]), 82 bp downstream of
P1. The fused disinfectant determinant and sulfonamide gene
qacE1/sul1 was found at the 3-CS end. The integron con-
sisted of four antimicrobial resistance gene cassettes (Fig. 1).
Located at the first position downstream of the 5-CS was the
ML blaIMP-16, which was flanked by typical features of a gene
cassette, namely, a core site (GTTACGC), an inverse core site
(TTCTAAC), and a 59-be (Fig. 2). This 59-be was 133 bp in
length and showed the greatest identity to the 59-be from
IMP-11, which has been found in P. aeruginosa (EMBL/Gen-
Bank/DDBJ accession no. AB074437) and A. baumannii
(EMBL/GenBank/DDBJ accession no. AB074436) strains iso-
lated in Japan. The blaIMP-16 59-be sequence differed by 11 of
132 bp (90.6% identity) from the blaIMP-11 59-be sequence.
blaIMP-16 sequence analysis and its deduced protein se-
quence. blaIMP-16 encoded a putative protein of 246 amino
acids and presented a GC content of 38.5%. The N terminus
of the protein showed features typical of bacterial signal pep-
tides that target proteins to the periplasmic space, and the
most likely cleavage site was identified between the alanine
and glycine residues (Fig. 2). This produced a mature protein
FIG. 1. Schematic representation of the class 1 integron-containing blaIMP-16 gene cassette from clinical isolate P. aeruginosa 101–4704. Boxes,
inserted genes; arrows, transcriptional orientations; black circles, 59-be’s; white circle, attI1 recombination site; lines, DNA of the inserts contained
within recombinant plasmids pREM-1, pREM-2, pREM-3, and pREM-4; arrowheads, primer positions and their orientations; M, start codon;
asterisk, the location of the stop codon for the particular gene.
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of 25,266 Da with a theoretical pI of 6.5. The results of the
analytical IEF experiment gave a pI that was in accordance
with the theoretical pI of blaIMP-16 (data not shown). IMP-16
showed six unique amino acid differences compared to the
sequences of the other IMP variant, namely, E50D, V74F,
T88A, T122S, V183L, and K252R, and displayed the greatest
identities to IMP-11 (90.3%) and IMP-8 (89.5%), with 21 and
24 amino acid differences at the level of the mature protein,
respectively (Fig. 3). The ML active site implicated in the
binding of zinc ions, as well as residues known to not tolerate
substitutions, were conserved, as previously described for all
the other IMP-type enzymes (Fig. 3).
Antimicrobial resistance pattern of E. coli DH5 harboring
recombinant plasmid pREM-4. blaIMP-16 was amplified by
PCR and ligated into a vector, pPCRScriptCam SK(), in
order to create recombinant plasmid pREM-4, which was ex-
pressed in E. coli DH5	 (Fig. 1). E. coli DH5	 harboring
recombinant plasmid pREM-4 showed an antimicrobial resis-
tance profile consistent with that observed for the index strain,
strain 101-4704. It showed some degree of resistance to ben-
zylpenicillin, ampicillin, amoxicillin-clavulanate, ceftazidime,
and cefotaxime and decreased susceptibility to cefepime, pip-
eracillin, piperacillin-tazobactam, imipenem, and meropenem.
The index strain as well as E. coli DH5	(pREM-4) remained
highly susceptible to the monobactam aztreonam (Table 2).
ML resistance marker transfer experiments. Conjugation
experiments between rifampin-susceptible (Rifs) strain P.
aeruginosa 101-4704 and Rifr strain E. coli K-12, as well as P.
aeruginosa 101-4704 and Rifr strain P. aeruginosa pA01, did not
yield transconjugants. Despite repeated attempts, analysis of
plasmid DNA from P. aeruginosa 101-4704 did not identify any
plasmid, and transformation experiments were unsuccessful.
As a -lactam resistance marker was not transferred to the
recipient strains, even in the conjugation experiments,
blaIMP-16 is likely encoded by the chromosome and is not
carried on a plasmid.
Genetic context of fused gene aac(6)-30/aac(6)-Ib. An
open reading frame (ORF) of 984 bp was detected immedi-
ately downstream of blaIMP-16. The ORF was preceded by a
ribosome-binding site and potentially encoded a protein of
FIG. 2. DNA and amino acid sequences of the blaIMP-16-carrying integron and its gene. The start and stop codons of the ORFs are indicated
by horizontal arrows and asterisks, respectively. The corresponding predicted protein translation is reported below the DNA sequence. The double
slashes represent the putative cleavage site of the signal sequence of IMP-16. The conserved 7-bp core sites located at the cassette boundaries and
the 7-bp inverse core sites located at the left end of each 59-be are boxed. The recombination crossover sites are indicated by vertical arrows. The
59-bes are in italic; and their conserved sequences are highlighted in boldface and are labeled 1L, 2L, 2R, and 1R. The entire sequence has been
assigned EMBL/GenBank/DDBJ accession number AJ584652.
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36.7 kDa. This ORF consisted of a novel gene cassette, namely,
aac(6)-30 fused with the aac(6)-Ib gene. aac(6)-30 was also
flanked by typical features, but it presented a shortened 59-be
of 19 bp, including the core and inverse core sites (Fig. 2).
aac(6)-Ib had a core site with a 1-bp mismatch, an A residue
(in boldface) instead of the usual G residue (ATTAGGC) and
an inverse core site (GCCTAAC), and the translation could
start at the GTG codon located 19 bp downstream from its
core site or at either one of the ATG codons located farther
downstream (Fig. 2) (11, 28).
aac(6)-30/aac(6)-Ib sequence analysis and its deduced
protein sequence. The deduced amino acid sequence of the
aac(6)-30 product possessed the highest similarity (52.7%) to
previously described protein AAC(6)-29b (EMBL/GenBank/
DDBJ accession no. AAK26254) (Fig. 4) (32). Except for the
substitution aspartate-1713valine, AAC(6)-Ib contained a se-
quence homologous to the previously described product of
aac(6)-Ib (EMBL/GenBank/DDBJ accession no. AAA25685),
which encodes the aminoglycoside 6-N-aminoglycoside acetyl-
transferase. This gene was characterized by a leucine-903serine
substitution and specified a type II enzyme that conferred resis-
tance to gentamicin but not to amikacin (19).
IMP-16 purification and kinetics. The IMP-16 enzyme was
overproduced and purified from E. coli(pREM-4) by fast-per-
formance liquid chromatography, followed by a gel permeation
chromatography step. The yield of the IMP-16 purified protein
preparation was 0.3 M, which appeared to contain a single
band just under the band at 28.8 kDa, and it was estimated to
be 95% pure (data not shown). Steady-state kinetics demon-
strated that IMP-16 was able to hydrolyze several -lactams,
including penicillins, narrow- to expanded-spectrum cephalo-
sporins, and carbapenems. Kinetic values showed that the
cephalosporins and the carbapenems were the best substrates
(kcat/Km ratios, 0.15 M
1  s1), while penicillins were uni-
formly poorer substrates (kcat/Km ratios, 0.13 M
1  s1)
(Table 3). No hydrolysis of cefoxitin or aztreonam was ob-
served.
Expression of aminoglycoside-modifying genes in E. coli
DH5. The P. aeruginosa index strain was resistant to kana-
mycin, tobramycin, gentamicin, and netilmicin but was suscep-
FIG. 3. Amino acid alignment of the IMP-16 protein sequence with those of IMP-type enzymes. Differences in the amino acid sequences are
noted by insertion of a single letter representing the amino acid change within that particular sequence. Asterisks under the IMP-16 sequence
represent amino acids involved in the coordination of zinc ions, and residues known to not tolerate substitutions are underlined. References for
each sequence are as follows: IMP-1 (20), IMP-2 (37), IMP-3 (15), IMP-4 (4), IMP-5 (7), IMP-6 (52), IMP-7 (13), IMP-8 (51), IMP-9
(EMBL/GenBank accession no. AY033653), IMP-10 (16), IMP-11 (EMBL/GenBank accession no. AB074437), IMP-12 (8), IMP-13 (46), and
IMP-16 (this study). Numbering is according to the scheme for class B -lactamases (12).
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tible to amikacin and isepamicin (Table 2). In order to evaluate
the functional status of AAC(6)-30 and AAC(6)-Ib, their
respective genes, as well as the fused form, were amplified by
PCR and ligated into the pPCRScriptCam SK() vector, cre-
ating recombinant plasmids pREM-1, pREM-2, and pREM-3
(Fig. 1). E. coli harboring pREM-1 [AAC(6)-30] showed de-
creased susceptibilities to amikacin, kanamycin, tobramycin,
and neomycin but remained susceptible to gentamicin, sisomi-
cin, isepamicin, and netilmicin. E. coli harboring pREM-2
[aac(6)-30/aac(6)-Ib] showed decreased susceptibilities to all
aminoglycosides tested, apart from isepamicin. Strikingly, E.
coli harboring pREM-2 [AAC(6)-Ib] did not confer the ex-
pected AAC(6)-II phenotype, since it remained susceptible to
gentamicin. Increases in the MICs of kanamycin, tobramycin,
and sisomicin were observed (Table 2).
DISCUSSION
Multidrug-resistant Pseudomonas sp. isolates continue to be
a growing concern, particularly for institutions where carbap-
enems are readily used. Many hospitals in Brazil routinely use
carbapenems and expanded-spectrum cephalosporins to treat
infections caused by gram-negative organisms, which provides
selective pressure for the development of resistance. P. aerugi-
nosa 101-4704 remained susceptible to amikacin, aztreonam,
piperacillin, and fluoroquinolones, yet it displayed high-level
resistance to most other aminoglycosides and -lactams (in-
cluding carbapenems), a resistance phenotype that is becoming
common in Brazil.
The kinetics of IMP-16 showed that the enzyme hydrolyzes
-lactams less efficiently than IMP-1 does (Table 3). However,
similar to other IMP variants, IMP-16 demonstrated an overall
preference for cephalosporins and carbapenems rather than
penicillins. The poor hydrolytic activity of IMP-16 toward pip-
eracillin (kcat/Km ratio, 0.09 M
1  s1) was consistent with
the relatively low increase in the piperacillin MIC for E. coli
harboring recombinant plasmid pREM-4. The kcat/Km ratios of
IMP-16 for penicillins showed very similar results (0.09 to 0.13
M1  s1, which may suggest that the structure of the C-6
side chain, which varies among penicillins, did not affect the
hydrolytic activity of IMP-16.
The kinetic data also revealed a lower kcat/Km value for
imipenem (0.36 M1  s1), essentially due to a higher Km
value. Other IMP variants, such as IMP-3 and IMP-12, also
showed similar kcat/Km ratios (0.08 and 0.26 M
1  s1, re-
spectively), apparently due to the S262G substitution (8, 15).
This amino acid mutation was not present in IMP-16, and no
other amino acid changes were present in IMP-3, IMP-12, and
IMP-16 which were absent from the other IMP variants with
higher levels of imipenem hydrolysis. However, IMP-16
showed six unique amino acid substitutions (Fig. 3), which
included V74F, located seven residues after the IMP loop site,
and T122S, just adjacent to the zinc ligand Asp120. These
changes may have contributed to the IMP-16 hydrolytic activ-
ity.
The 5 region of the contiguous gene aac(6)-30/aac(6)-Ib,
located downstream from blaIMP-16, was associated with a
shortened 59-be. To date, there have been only three cases in
which a complete cassette was also found in an alternative
form with a shorter 59-be (30). aac(6)-30 is the second case in
which the complete version of the gene has not yet been found
(33). It appears likely that the creation of the short aac(6)-30
TABLE 2. Antimicrobial susceptibility profiles of blaIMP-16-carrying clinical isolate P. aeruginosa 101-4704; E. coli DH5	 harboring
recombinant plasmid pREM-1, pREM-2, pREM-3, or pREM-4; and the E. coli DH5	 recipient strain
Antimicrobial class and agent
MIC (g/ml)
P. aeruginosa
101-4704
E. coli DH5	
(pREM-1) aac(6)-30
E. coli DH5	 (pREM-2)
aac(6)-30/aac(6)-Ib
E. coli DH5	
(pREM-3) aac(6)-Ib
E. coli DH5	
(pREM-4) blaIMP-16
E. coli
DH5	
-Lactams
Benzylpenicillin 256 —a — — 64 0.5
Ampicillin 256 — — — 128 2
Amoxacillin-clavulanate 256/128 — — — 128/64 2
Aztreonam 4 — — — 1 0.5
Ceftazidime 256 — — — 32 0.06
Cefotaxime 256 — — — 64 0.12
Piperacillin 32 — — — 4 1
Piperacillin-tazobactam 4/4 — — — 4/4 0.5
Ticarcillin 128 — — — 128 2
Ticarcillin-cavulanate 128 — — — 128 2
Cefepime 64 — — — 4 0.06
Imipenem 256 — — — 0.5 0.12
Meropenem 128 — — — 0.25 0.06
Aminoglycosides
Gentamicin 16 1 4 1 — 0.25
Amikacin 4 2 8 2 — 0.5
Kanamycin 128 8 32 16 — 0.5
Neomycin 8 4 8 2 — 0.25
Netilmicin 128 1 4 2 — 0.5
Sisomicin 64 1 4 4 — 0.25
Isepamicin 2 1 1 1 — 0.12
Tobramycin 32 4 8 8 — 0.25
a —, not applicable.
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59-be occurred through misreading of the 2L 59-be conserved
sequence for the natural core sequence during an excision
event, as described previously (49). Given the short 59-be, it is
possible that the aac(6)-30 and aac(6)-Ib genes were fused
and may move as a single unit on excision.
The E. coli strain harboring recombinant plasmid pREM-1
[AAC(6)-30] did not demonstrate an obvious resistance pro-
file; however, a slight increase in aminoglycoside MICs was
observed for the strain, suggesting that its complete form may
be functional and expresses an AAC(6)-I phenotype. This
phenotype can be inferred because (i) this class of proteins is
more active against tobramycin and amikacin than gentamicin
(42), and (ii) AAC(6)-30 revealed a large number of the same
conserved residues present in all related members of the
AAC(6) family (motifs A, B, E, and F) (Fig. 4). However, like
AAC(6)-29a and AAC(6)-29b, AAC(6)-30 did not contain
the G conserved motif, commonly present in most of the
AAC(6) subfamily members (24), probably due to a trunca-
tion event in the C-terminal region of these proteins (Fig. 4)
(32).
Comparison of the MICs for E. coli harboring the three
recombinant plasmids showed that pREM-2 [AAC(6)-30/
AAC(6)-Ib] conferred broad aminoglycoside-modifying en-
zyme activity, similar to that of the index strain (strain 101-
4704), and a resistance profile similar to that of strain 101-
4704. The MICs for E. coli harboring plasmid pREM-2 were
between two- and fourfold higher than those observed for E.
coli harboring plasmid pREM-1 [AAC(6)-30] and E. coli har-
FIG. 4. Comparison of the deduced amino acid sequences of AAC(6)-30 with those members of the AAC(6) family. Differences in the amino
acid sequences are noted by insertion of a single letter representing the amino acid change within that particular sequence. Motifs A, B, C, and
D are conserved among all members of the AAC(6) family, while motifs E, F, and G are conserved among most of the members of the AAC(6)
subfamily. References for each sequence are as follows: AAC(6)-Ic (43); AAC(6)-If (45); AAC(6)-Ig (18); AAC(6)-Ih and AAC(6)-Ij (17);
AAC(6)-Ik (38); AAC(6)-Ir, AAC(6)-Is, AAC(6)-It, AAC(6)-Iu, AAC(6)-Iv, AAC(6)-Ix, and AAC(6)-Iw (39); AAC(6)-Iy (23); AAC(6)-
29a and AAC(6)-29b (32); and AAC(6)-30 (this study).
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boring plasmid pREM-3 [AAC(6)-Ib]. The phenotype ex-
pressed by the strain harboring recombinant plasmid pREM-2
may be characterized as an AAC(6)-II type with an additional
decreased susceptibility to amikacin.
Although it is still not clear, the phenotype expressed by the
strain harboring recombinant plasmid pREM-2 may be due to
the expression of the fused enzyme [AAC(6)-30/AAC(6)-Ib]
alone or even expression of the fused enzyme accompanied by
the additional expression of AAC(6)-Ib, since aac(6)-Ib
contains its own promoter and ribosome-binding site, which
are essential for transcription and translation. Thus, the ami-
noglycoside resistance profile may be maximized due to the
expression of both proteins, leading to a synergistic effect.
However, the gentamicin and amikacin MICs for the strain
harboring recombinant plasmid pREM-2 were fourfold higher
than those for the strain harboring pREM-1 and pREM-3,
suggesting the activity of a unique protein rather than the
additive effects of two enzymes.
The association of mobile ML genes with aminoglycoside
resistance genes has become very common. blaIMP, blaVIM, and
the recently discovered gene blaGIM-1 (M. Castanheira, R. E.
Mendes, F. Schmitz, M. A. Toleman, R. N. Jones, and T. R.
Walsh, Abstr. 43rd Intersci. Conf. Antimicrob. Agents Che-
mother., abstr. C1-669, p. 76, 2003) all represent ML genes
associated with aminoglycoside-modifying enzymes. The ex-
ception among the ML genes is blaSPM-1, which does not
appear to be associated with an integron (34, 48). In the ma-
jority of cases the aminoglycoside resistance genes appear to
be functional and confer significant resistance. Their mobili-
zation with -lactamase genes that confer broad-spectrum
-lactam resistance and the fact that both classes of enzymes
cannot be neutralized by clinically available enzyme inhibitors
result in a situation of great concern regarding the treatment of
infections caused by multidrug-resistant gram-negative bacilli.
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